E-Mail
Women awaiting liver transplants in the United States are known to be about one-third more likely than men to become too ill to undergo surgery or die before receiving a liver. Now a study headed by UC San Francisco and Columbia University highlights the role that frailty plays in this gender gap.
The study followed 1,405 patients with cirrhosis, of whom 41 percent were women, awaiting liver transplantation at nine transplant centers in the United States. The men, whose ages ranged from 49 to 63, were more likely to have chronic hepatitis C and alcoholic liver disease (27 percent versus 22, and 33 percent versus 19 percent). The women, whose ages ranged from 50 to 63, were more likely to have non-alcoholic fatty liver disease and autoimmune cholestatic liver disease (23 percent versus 16 percent, and 23 percent versus 9 percent).
Prof. Karen Avraham and Shahar Taiber
A new study at Tel Aviv University presents an innovative treatment for deafness, based on the delivery of genetic material into the cells of the inner ear. The genetic material ‘replaces’ the genetic defect and enables the cell to continue functioning normally.
The scientists were able to prevent the gradual deterioration of hearing in mice with a genetic mutation for deafness. They maintain that this novel therapy could lead to a breakthrough in treating children born with various mutations that eventually cause deafness.
The study was led by Prof. Karen Avraham and Shahar Taiber, a student in the combined MD-PhD track, from the Department of Human Molecular Genetics and Biochemistry at the Sackler Faculty of Medicine, and the Sagol School of Neuroscience, and Prof. Jeffrey Holt from Boston Children’s Hospital and Harvard Medical School. Additional contributors included Prof. David Sprinzak from the School of Neurobiology, Biochemistry
Researchers develop new gene therapy for deafness ANI | Updated: Dec 27, 2020 22:01 IST
Tel Aviv [Israel], December 27 (ANI): An innovative treatment for deafness, based on the delivery of genetic material into the cells of the inner ear, gas been developed by researchers from Tel Aviv University. The genetic material replaces the genetic defect and enables the cells to continue functioning normally.
The scientists were able to prevent the gradual deterioration of hearing in mice that had a genetic mutation for deafness. They maintain that this novel therapy could lead to a breakthrough in treating children born with various mutations that eventually cause deafness.
Study presents novel gene therapy for deafness
A new study from Tel Aviv University (TAU) presents an innovative treatment for deafness, based on the delivery of genetic material into the cells of the inner ear. The genetic material replaces the genetic defect and enables the cells to continue functioning normally.
The scientists were able to prevent the gradual deterioration of hearing in mice that had a genetic mutation for deafness. They maintain that this novel therapy could lead to a breakthrough in treating children born with various mutations that eventually cause deafness.
The study was led by Professor Karen Avraham of the Department of Human Molecular Genetics and Biochemistry at TAU s Sackler Faculty of Medicine and Sagol School of Neuroscience. The paper was published in
Dec 24, 2020
The innovative therapy replaces defective genes with healthy genes and may prevent deafness in children born with genetic mutations that cause hearing loss.
By TPS
Israeli scientists at Tel Aviv University have developed a gene therapy for deafness, a breakthrough that may help in the treatment of children with hearing loss.
The innovative therapy, replacing defective genes with healthy genes, may prevent deafness in children born with genetic mutations that cause hearing loss.
The scientists developed a treatment for genetic deafness caused by a specific mutation identified for the first time in Israeli families, and then in the United Kingdom and Turkey.